Morinda

Morinda: A Comprehensive Encyclopedic Reference

1. Identity and Botanical Classification

1.1 The Genus Morinda

The genus Morinda (family Rubiaceae) includes approximately 102 species and is distributed across tropical, subtropical, and temperate regions. Within the broader botanical and dietary supplement literature, the term "Morinda" most commonly refers to two distinct species that have attracted sustained scientific and commercial attention: Morinda citrifolia L. (noni) and Morinda officinalis F.C. How (Ba Ji Tian). A third species, Morinda lucida, is employed primarily in West African traditional medicine. These species are not interchangeable botanically or pharmacologically, although they share genus membership and certain chemical compound families.

1.2 Morinda citrifolia L. (Noni / Indian Mulberry)

Morinda citrifolia (Rubiaceae) is an evergreen shrub whose ripe fruit has a strong butyric acid smell and flavor. The leaves and especially the fruit are consumed in different forms by various communities throughout the world, while the root is also used as a dye. Morinda citrifolia has a variety of regionally significant names, including noni, great morinda, and Indian mulberry. It is native to Australasia and Southeast Asia and is naturalized throughout the Pacific region and the tropics.

Common names for M. citrifolia include: noni (Hawaiian/Polynesian), Indian mulberry, great morinda, cheese fruit, and Ba Ji Tian (a term sometimes applied to both this species and to M. officinalis depending on the regional tradition). Other commercially employed names include Tahitian Noni Juice® and Xeronine.

Morinda citrifolia is a small, tropical fruit tree commonly known as Indian Mulberry, Ba Ji Tian, or Noni, which has been used as a food and an herbal remedy for centuries in Polynesia and Southeast Asia.

1.3 Morinda officinalis F.C. How (Ba Ji Tian)

Morinda officinalis How, belonging to the genus Morinda of the family Rubiaceae, is a perennial vine naturally distributed in southern China and northern Vietnam. A commonly used traditional Chinese medicinal plant, it was first reported in the Shen Nong Ben Cao Jing and accepted in the Chinese Pharmacopoeia in 1963. The roots of M. officinalis, named bajitian in traditional Chinese medicine, are one of the four famous southern herbs from the Lingnan region of southern China. Scientifically, Morinda officinalis is the most common name of this species, but it is also known as Gynochthodes officinalis (F.C. How) Razafim. & B. Bremer.

1.4 Common Preparations and Dosage Forms

For M. citrifolia, commercially available preparations include:

• Fruit juice — the dominant commercial form, typically prepared by fermenting or pressing ripe fruit; sold under brand names such as Tahitian Noni Juice®
• Fruit puree and concentrate — approved as a novel food ingredient in the European Union
• Capsules and tablets — containing dried fruit powder or standardized extracts
• Leaf infusions (teas) — prepared from dried leaves
• Topical preparations — used in cosmetic and skincare applications

Noni juice as a dietary supplement has driven more research focus on the compositional analysis of the fruit, including phenols, polysaccharides, coumarins, fatty acids, cyclic enol ether terpenes, flavonoids, carotenoids, essential oils, and other components; the composition of vitamins, amino acids, and trace minerals has also been reported.

For M. officinalis, preparations include:

• Decoctions of dried root — the classical TCM preparation
• Capsules containing oligosaccharide extracts — a modern pharmaceutical form approved in China for depression
• Nourishing soups and tonics — used as functional foods in southern China
• Wine preparations and powders — used in combination TCM formulas

---

2. Traditional and Historical Use

2.1 Morinda citrifolia in Polynesian, Hawaiian, and Pacific Island Traditions

Morinda citrifolia, commonly referred to as noni, is a Polynesian medicinal plant with over 2,000 years of traditional use. Noni is believed to be among the original plants that Pacific islanders brought with them in their voyaging canoes; they valued the plant for its medicine and dyes.

Remedies from isolated Polynesian cultures, such as that of Rotuma, illustrate traditional indications that focus upon leaves, roots, bark, and green fruit, primarily for topical ailments. All parts of the plant, including its fruit, leaves, bark, and root, are used by peoples native to Southeast Asia and the Pacific. The fruit is also used by Australian Aboriginal peoples.

In Polynesian culture, Morinda citrifolia is believed to be a gift from the gods and to be connected to the volcano goddess Pele. Polynesian peoples further associate the plant with the revival of the demigod Maui. Green fruit, leaves, and root or rhizomes might have been used in Polynesian cultures as a general tonic, in addition to its traditional place in Polynesian culture as a famine food.

Anecdotally collected Hawaiian remedies that employ noni fruit illustrate changing usage patterns, with shifts in recent times toward preparation of juice made of ripe or decaying fruit. Its fruit is fermented for juice and is used in curry, cooked rice dishes, and sauces.

Morinda citrifolia L., also known as noni, has been used traditionally as a folk remedy for many diseases, including diabetes, hypertension, and cancer in Polynesia, South and Southeast Asia, Northeastern Australia, and the Caribbean, owing to its diverse biological activities.

2.2 Morinda citrifolia in Indian, Southeast Asian, and Caribbean Traditions

The bark, stem, root, leaf, and fruit have been used traditionally as a folk remedy for many diseases including diabetes, hypertension, and cancer. In Indian traditional medicine (Ayurveda), the plant is known as Ashyuka and has historically been used for its analgesic and anti-inflammatory properties, applied both internally and topically. In the Caribbean and Central America, where the plant was introduced by migrating peoples, fruit preparations have been used for pain management and digestive complaints.

2.3 The Transition to Commercial Use

Ralph M. Heinicke promoted a wide range of claims about noni, and these seem to have fueled much of the current commercial interest in the plant. Recent studies of the proliferation of commercial products have shown that noni product manufacturers promote a range of therapeutic claims. These claims are based upon traditional Polynesian uses, Heinicke's ideas, and fragments of recent scientific studies including the activity of noni in the treatment of cancer. Noni juice was approved as a novel food by the European Commission in 2003.

2.4 Morinda officinalis in Traditional Chinese Medicine

M. officinalis, a commonly used traditional Chinese medicinal plant, was first reported in the Shen Nong Ben Cao Jing and accepted in the Chinese Pharmacopoeia in 1963. The Shen Nong Ben Cao Jing is the earliest surviving Chinese pharmacopoeia, dating to approximately the first or second century CE, making documented use of M. officinalis extremely ancient.

The medicinal plant Morinda officinalis How and its root have long been used in traditional medicines in China and northeast Asia as tonics for nourishing the kidney, strengthening the bone, and enhancing immune function in the treatment of impotence, osteoporosis, depression, and inflammatory diseases such as rheumatoid arthritis and dermatitis.

M. officinalis is a lianoid shrub mainly growing in mountains and forests of tropical and subtropical regions. Now it can be artificially cultivated. The application of M. officinalis root can be dated back to the late Qing Dynasty. It is now cultivated in Guangdong, Guangxi, and Fujian provinces of China and is regarded as a famous-region medicinal herb of Guangdong province. According to the book "Yaowu Chuchanbian" (A.D. 1930) written by CHEN Renshan, M. officinalis from Qingyuan, Sankeng, and Luoding of Guangdong province is regarded as the top-grade medicinal material.

Morindae officinalis radix (MOR), the dried root of medicinal plant Morinda officinalis How (Rubiaceae), has long been used in tonics and nutrient supplements — including healthcare products, nourishing soups, and drinks — in the southeast region of China for its action in nourishing the kidney, anti-osteoporosis, immune-enhancing effects, and for alleviating a wide spectrum of diseases.

---

3. Key Constituents and Active Compounds

3.1 Morinda citrifolia: Phytochemical Profile

The noni plant contains more than 160 chemical constituents, of which 120 are considered nutraceuticals; recognized phytochemical constituents include scopoletin, anthraquinones, octoanoic acid, vitamin C, terpenoids, β-sitosterol, polysaccharides, flavone glycosides, linoleic acid, carotene, alizarin, gallic acid, rosmarinic acid, amino acids, aucubin, L-asperuloside, ursolic acid, quercetin, rutin, and proxeronine.

Studies on the phytochemistry of M. citrifolia have focused on the roots, leaves, and fruits, with anthraquinones, iridoids, flavonoids, and coumarins as the main compounds; among these, damnacanthal, scopoletin, rutin, ursolic acid, and asperuloside are the main components. The compounds isolated from the roots are dominated by anthraquinone compounds (e.g., damnacanthal and sterols). The M. citrifolia leaves contain a variety of iridoids, flavonoids, and triterpenoids.

Anthraquinones

Anthraquinones, in particular damnacanthal, morindone, morindin, and aucubin, asperuloside, and scopoletin, have been prominently identified. These phenolics exhibit their antioxidative activity via several mechanisms of action, including as reducing agents, singlet oxygen quenchers, hydrogen donating antioxidants, free radical scavengers, and metal ion chelators.

Other anthraquinones isolated from M. citrifolia include alizarin, morindadiol, nordamnacanthal, rubiadin, ibericin, tectoquinone, lucidin, damnacanthol-ω-ethyl ether, lucidin-ω-butyl ether, rubiadin-dimethyl ether, rubiadin-1-methyl ether, rubiadin-3-methyl ether, and 1-hydroxy-2-methyl-9,10-anthraquinone.

Iridoids

Key iridoids include aucubin, asperulosidic acid, deacetylasperulosidic acid (DAA), and asperuloside. Isolation from M. citrifolia fruits has also yielded iridoid glucosides such as 6alpha-hydroxyadoxoside and 6beta,7beta-epoxy-8-epi-splendoside, along with asperuloside, asperulosidic acid, borreriagenin, citrifolinin B epimers, deacetylasperuloside, and dehydromethoxygaertneroside, among other known iridoids and non-iridoid compounds. Deacetylasperulosidic acid is quantitatively dominant among the iridoids: deacetylasperulosidic acid accounts for approximately 78% of the total iridoid content in commercial noni juice products.

Coumarins: Scopoletin

Scopoletin (6-methoxy-7-hydroxycoumarin) is among the most pharmacologically studied single compounds from M. citrifolia. Scopoletin is an active principle obtained from Morinda citrifolia that efficiently quenches oxidative stress through DJ-1/Nrf2 signaling. Administration of M. citrifolia extract has been shown to lessen protein aggregation as evidenced by decreased levels of nitrotyrosine and α-synuclein. In vitro studies revealed that scopoletin lessened rotenone-induced apoptosis in SH-SY5Y cells through preventing oxidative injury. Particularly, scopoletin markedly upregulated DJ-1, which then promoted the nuclear translocation of Nrf2 and transactivation of antioxidant genes.

Flavonoids

Key flavonoids include kaempferol and rutin. Rutin and other flavonols contribute to the plant's antioxidant and anti-inflammatory profile.

Polysaccharides

Polysaccharides and iridoids demonstrate dual antioxidant and anti-inflammatory effects via gut microbiota regulation. Among the notable polysaccharides, nonioside A has been identified in the fruit.

Xeronine and Proxeronine (Disputed)

Xeronine, a small alkaloid that has been patented (US4543212), is one of the bioactive compounds proposed for noni fruit, believed to be capable of modifying the molecular structure of specific inactive proteins thereby regulating proper folding to active enzymes. Despite reports of the potential of xeronine as a therapeutic agent, its presence is controversial and its structure has not been fully explored. The proxeronine theory was primarily promoted by biochemist Ralph Heinicke, and there remains insufficient peer-reviewed structural and mechanistic verification to consider this a firmly established active compound. Claims based solely on this theory should be treated with caution.

3.2 Morinda officinalis: Phytochemical Profile

Iridoid glycosides, anthraquinones, polysaccharides, and oligosaccharides are the main bioactive constituents of M. officinalis.

Oligosaccharides and Polysaccharides

The main active components of Morinda officinalis include sugars, anthraquinones, and iridoids. Among these, sugars — including monosaccharides, polysaccharides, and oligosaccharides — are considered the primary bioactive constituents. The polysaccharides in M. officinalis mainly consist of glucose and fructose, which have antifatigue, antidepressant, and anti-osteoporosis roles.

Iridoids of M. officinalis

Monotropein, a kind of iridoid compound, has potent anti-inflammatory and analgesic effects and is the main component of M. officinalis for dispelling wind and eliminating dampness.

Anthraquinones of M. officinalis

Phytochemical studies have shown that M. officinalis contains anthraquinones, iridoids, flavonoids, polysaccharides, volatile oils, and other important compounds. Anthraquinones are one of the main active components and mainly contain physcion, rubiadin-1-methylether, anthragallol-2-methylether, etc., which have various biological activities such as antibacterial, anticancer, anticoagulant, and antiviral activities.

---

4. Mechanisms of Action

4.1 Antioxidant Mechanisms

Systematic analyses reveal that noni-derived compounds exhibit potent free radical scavenging capacity (e.g., DPPH/ABTS inhibition), upregulate endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase), and modulate key pathways such as Nrf2/Keap1 and NF-κB.

4.2 Anti-Inflammatory Mechanisms

Studies on Hawaiian noni fruit juice identified compounds with anti-inflammatory activity in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages; five compounds — asperulosidic acid, rutin, nonioside A, a fatty acid glucoside, and tricetin — were isolated by bioassay-driven phytochemical analysis and shown to inhibit the production of nitric oxide (NO), a proinflammatory mediator, in LPS-stimulated macrophages.

4.3 Anticancer Mechanisms

Damnacanthal, an anthraquinone compound isolated from the roots of M. citrifolia L. (noni), has been used for traditional therapy in several chronic diseases, including cancer. Although noni has long been consumed in Asian and Polynesian countries, the molecular mechanisms by which it exerts several benefits are starting to emerge. Treatment of MCF-7 cells with damnacanthal indicated an antiproliferative activity; damnacanthal inhibited the growth of MCF-7 breast cancer cells at a concentration of 8.2 μg/mL for 72 hours, was found to induce cell cycle arrest at the G1 checkpoint in MCF-7 cells, and induced apoptosis as determined by Annexin V/PI dual-labeling, acridine-orange/PI dyeing, and caspase-7 expression.

Various demonstrated anticancer properties in different cancer models have been reported, with multiple mechanisms including antitumor, antiproliferative, pro-apoptotic, antiangiogenesis, antimigratory, anti-inflammatory, and immunomodulatory activities.

4.4 Antidepressant Mechanisms (M. officinalis)

Morinda officinalis oligosaccharides (MOO) are an oral drug approved in China for the treatment of depression. However, MOO is poorly absorbed, meaning their antidepressant mechanism had not been straightforwardly elucidated through direct pharmacokinetics. Research has subsequently demonstrated that MOO exerts antidepressant effects partly through modification of gut microbiota, thereby promoting 5-hydroxytryptophan (5-HTP) production and increasing serotonin levels in the brain.

---

5. Scientific Evidence by Area of Use

5.1 Antioxidant Activity

Human/Clinical Evidence (Moderate): To evaluate antioxidant activity in humans, Tahitian noni juice (TNJ) was evaluated in a 30-day, double-blind, placebo-controlled clinical trial with 285 current heavy smokers. Research participants were randomly assigned to three daily treatment groups: 118 mL placebo, 29.5 mL TNJ, and 118 mL TNJ. Plasma superoxide anion radicals (SAR) and lipid hydroperoxide (LOOH) levels were measured pre- and post-intervention. After 30 days, mean SAR decreased significantly in both TNJ dose groups (P < 0.01 and P < 0.001, respectively). The most significant effect of TNJ in this trial was on mean post-test plasma LOOH concentrations; in both TNJ groups, these were significantly less than pre-test values and the post-test mean of the placebo group.

Additionally, 245 heavy cigarette smokers completed a randomized, double-blind, placebo-controlled clinical trial designed to investigate the effect of noni juice on lipid hydroperoxide (LOOH)- and malondialdehyde (MDA)-DNA adducts in peripheral blood lymphocytes; volunteers drank noni juice or a fruit juice placebo every day for one month. Drinking 29.5–118 mL of noni juice significantly reduced adducts by 44.6–57.4%. The placebo, which was devoid of iridoid glycosides, did not significantly influence LOOH- and MDA-DNA adduct levels.

Evidence Characterization: These human trials demonstrate statistically significant antioxidant effects in a specific population (heavy smokers). Generalizability to healthy non-smoker populations has not been established in equivalent controlled studies. The evidence is promising but requires replication in broader populations.

5.2 Cardiovascular Risk Markers and Lipid Profiles

Human/Clinical Evidence (Moderate): 132 adult heavy smokers completed a randomized, double-blind, placebo-controlled clinical trial designed to investigate the effect of noni juice on serum cholesterol, triglyceride, LDL, HDL, high-sensitivity C-reactive protein (hs-CRP), and homocysteine; volunteers drank noni juice or a fruit juice placebo daily for one month. Drinking 29.5 mL to 188 mL of noni juice per day significantly reduced cholesterol levels, triglycerides, and hs-CRP. Decreases in LDL and homocysteine, as well as increases in HDL, were also observed among noni juice drinkers. The placebo, which was devoid of iridoid glycosides, did not significantly influence blood lipid profiles or hs-CRP.

Evidence Characterization: Findings are statistically significant in the enrolled smoker population and point toward the iridoid fraction as the likely active component. These results should be interpreted cautiously: the study population has particularly elevated baseline oxidative stress and dyslipidemia. Results have not been replicated in populations without smoking-related oxidative stress.

5.3 Anti-Inflammatory Effects

Human/Clinical Evidence (Limited): A prospective, randomized, double-blind, placebo-controlled trial was conducted in 100 university students aged 18 years and older over three menstrual cycles to evaluate the effect of 400 mg of noni capsules twice daily compared with placebo on pain and menstrual blood loss in the treatment of primary dysmenorrhoea. Of the 1,027 women screened, 100 eligible women were randomized; of those completing the study, 42 were assigned to noni and 38 to placebo.

Animal/Preclinical Evidence: Since noni is used to treat rheumatoid arthritis in traditional oriental medicine, researchers determined that noni might have anti-inflammatory properties by injecting aqueous extracts of noni derived from a slurry of ripe fruits (10 mg and 200 mg) into rats, and reported a dose-dependent reduction in paw inflammation triggered by an injected pro-inflammatory agent.

Evidence Characterization: Preclinical (animal and in vitro) evidence for anti-inflammatory activity is consistent across multiple studies. Human controlled trial evidence remains limited. The dysmenorrhoea trial provides one of the few prospective randomized human studies, but the sample size was small.

5.4 Anticancer Properties

Systematic Review Evidence: Morinda citrifolia L. has shown anticancer properties in in vitro, in vivo, and in clinical studies. A systematic review was conducted to collate scientific evidence using pre-determined keywords on five electronic databases (MEDLINE, CENTRAL, LILACS, Web of Science, EBSCOHost). A total of 51 clinical and preclinical studies comprising 41 efficacy studies and 10 safety studies were included.

Based on currently available clinical and preclinical efficacy evidence, noni is a potentially valuable medicinal plant in the treatment of cancer. The anticancer activities are evidently shown in breast and lung cancer models in which tumor volume is significantly decreased through apoptosis as well as disruption in cell migration and proliferation pathways.

In vitro and animal studies have shown potential antioxidant action, immune function stimulation, and antitumor activity, but there have been few trials in humans for any condition and no randomized controlled trials in cancer patients. An uncontrolled Phase 1 study showed no effect in tumor regression.

Evidence Characterization: The body of anticancer evidence is largely preclinical (cell culture and rodent models). While mechanisms such as damnacanthal's activity against tyrosine kinases are biologically plausible and have been demonstrated in vitro, no robust human randomized controlled trials have demonstrated anti-tumor efficacy in clinical oncology settings. Any therapeutic claims regarding cancer treatment must be viewed as highly preliminary.

5.5 Neuroprotective Effects

Preclinical Evidence: Research has tested the hypothesis that scopoletin, an active principle from M. citrifolia, efficiently quenches oxidative stress through DJ-1/Nrf2 signaling and ameliorates rotenone-induced Parkinson's disease (PD) in animal models. Despite reducing oxidative stress, administration of M. citrifolia extract lessened protein aggregation as evidenced by decreased levels of nitrotyrosine and α-synuclein. In vitro studies revealed that scopoletin lessened rotenone-induced apoptosis in SH-SY5Y cells through preventing oxidative injury.

Evidence Characterization: Neuroprotective evidence is entirely preclinical (animal and cell models). No human clinical trials for neurodegenerative conditions have been published as of the most recent review literature searched.

5.6 Antidepressant Effects (M. officinalis)

Regulatory / Clinical Evidence: Morinda officinalis oligosaccharides (MOO) are an oral drug approved in China for the treatment of depression. The oligosaccharide components exhibit significant antidepressant pharmacological activities; due to their antidepressant activities, Morinda officinalis oligosaccharide capsules not only have a significant antidepressant effect when used alone but also offer greater advantages when used in combination with other drugs.

Proposed Mechanism: Research has demonstrated that MOO exerts antidepressant effects partly by promoting 5-hydroxytryptophan (5-HTP) production through alteration of gut microbiota, thereby increasing serotonin in the brain — a mechanism distinct from classical serotonin reuptake inhibition and related to the gut-brain axis.

Evidence Characterization: The regulatory approval in China represents the strongest level of clinical evidence for any Morinda-derived compound in psychiatry. However, the specific clinical trial data underlying this approval have been primarily conducted and published in China, and the compound has not received regulatory approval in Western jurisdictions. Independent replication in large randomized controlled trials would further strengthen confidence.

5.7 Bone Health and Anti-Osteoporosis Effects (M. officinalis)

Preclinical Evidence: M. officinalis increases OPG expression, inhibits IL-6 and TNF-α expression, and promotes osteoblast proliferation in addition to the release of ALP and OC. After 4 weeks of ovariectomy, a study showed oral treatments with Morinda officinalis capsules prevented bone mass loss. Moreover, it raised plasma levels of serum ALP, TRAP, and OC, and increased bone mass and stopped the trabecular microarchitecture from deteriorating.

Pharmacological studies have indicated that the oligosaccharide components of Morinda officinalis possess significant anti-osteoporosis effects, highlighting their potential for further development and utilization.

Evidence Characterization: Evidence is primarily from in vitro and ovariectomized rodent models. There is a biologically plausible mechanism involving osteoblast stimulation and osteoclast suppression. Human clinical evidence specifically for osteoporosis treatment with M. officinalis preparations is limited in the English-language literature.

5.8 Reproductive and Aphrodisiac Effects (M. officinalis)

The roots of M. officinalis are widely used for the treatment of various diseases, such as impotence, infertility, abnormal menstruation, rheumatism, and arthralgia. Its dried roots are broadly used to treat various diseases such as impotence and rheumatism. The roots — an important traditional Chinese medicine and functional food — have been widely used for the treatment of sexual impotence, spermatorrhea, irregular menstruation, and female infertility for more than 2,000 years.

Various pharmacological and clinical studies have linked M. officinalis with aphrodisiac and immunomodulatory effects and anti-osteoporosis activity.

Evidence Characterization: The reproductive and aphrodisiac uses are strongly embedded in classical TCM texts and supported by animal studies. Human clinical evidence is limited and primarily comes from TCM clinical reports rather than rigorous randomized controlled trials that meet modern international methodological standards.

5.9 Antibacterial Properties

In Vitro Evidence: Extracts from noni leaves possessed antibacterial effects against Bacillus subtilis, Escherichia coli, Proteus vulgaris, and Staphylococcus aureus. Six phenolic compounds, including 5,15-dimethylmorindol, ferulic acid, p-hydroxycinnamic acid, methyl 4-hydroxybenzoate, methyl ferulate, and methyl 4-hydroxycinnamate, were identified as responsible compounds.

Evidence Characterization: Antibacterial evidence is exclusively in vitro. No human clinical trials for infectious diseases have been reported.

---

6. Body Systems and Health Areas Associated with Morinda

Based on the reviewed literature, Morinda species have been studied or used in relation to the following body systems:

• Cardiovascular system: Lipid-lowering, antioxidant protection of vascular tissues, anti-inflammatory (reduction of hs-CRP and homocysteine) — primarily via human studies in smokers.
• Immune system: Immunomodulatory polysaccharides (M. citrifolia fruit juice) have been studied in vitro and in animal models; anti-tumor immune stimulation is a proposed mechanism in cancer models.
• Musculoskeletal system: M. officinalis has traditional use and preclinical evidence for anti-osteoporotic and anti-rheumatic effects; promotion of osteoblast activity and inhibition of osteoclastogenesis have been demonstrated in cell and animal studies.
• Central nervous system: Scopoletin-mediated neuroprotection (Nrf2 pathway) studied in Parkinson's disease models; oligosaccharide-mediated antidepressant effects via gut-brain axis in M. officinalis.
• Reproductive system: M. officinalis root has a millennia-long history in TCM for impotence, infertility, and menstrual irregularities; supported by animal research and limited clinical data from TCM practice.
• Gastrointestinal system: Scopoletin acts as a 5-HT4 receptor agonist, influencing gastrointestinal motility; anthraquinones have mild laxative properties; noni may accelerate gastric emptying and modulate gut microbiota.
• Integumentary system (skin): Traditional topical use for skin infections, wound healing, and anti-aging; cosmetic preparations are marketed based on antioxidant constituent activity.
• Metabolic system: Animal studies have suggested hypoglycemic and hypolipidemic effects; human data in specific high-oxidative-stress populations support lipid-lowering activity.

---

7. Dosages Reported in Studies

The following dosages were reported in the specific studies identified above. These are presented solely as data points from published research and do not constitute dosage recommendations.

• Noni juice (antioxidant, lipid-profile trials in smokers): In the 30-day, double-blind, placebo-controlled trial with 285 heavy smokers, daily treatment groups received either 29.5 mL or 118 mL of Tahitian noni juice.
• Noni juice (lipid markers, 132-subject trial): Drinking 29.5 mL to 188 mL of noni juice per day significantly reduced cholesterol levels, triglycerides, and hs-CRP.
• Noni capsules (dysmenorrhoea trial): Patients received 400 mg noni capsules or placebo. The study design evaluated 400 mg of noni twice daily compared with placebo.
• DNA adduct reduction trial (smokers): Drinking 29.5–118 mL of noni juice significantly reduced DNA adducts by 44.6–57.4%.
• M. officinalis oligosaccharides (depression, approved in China): Morinda officinalis oligosaccharide capsules are the approved oral form, but precise dosing from the specific approval regimen was not reported in the English-language sources reviewed.

---

8. Safety Considerations and Drug Interactions

8.1 Hepatotoxicity

Hepatotoxicity attributed to noni juice has occasionally been severe and led to acute liver failure, which in at least one case necessitated emergency liver transplantation. Rechallenge studies have not been reported.

In a reported two-case series, the first patient underwent successful liver transplantation while the second patient recovered spontaneously after cessation of NONI juice. The temporal relationship between NONI intake and liver dysfunction and extensive exclusion of alternative causes of acute hepatitis confirmed herbal hepatotoxicity in both cases. Causality assessment using the CIOMS scale yielded a score of +5 ("possible") in case 1 and a score of +7 ("probable") in case 2.

The most likely hepatotoxic components of Morinda citrifolia were identified as anthraquinones.

A review of the first four cases by the European Food Safety Authority (EFSA) concluded that there was "no convincing evidence for a causal relationship between the acute hepatitis observed in the case studies reported and the consumption of noni juice." Nonetheless, LiverTox (NIH) rated the likelihood of noni juice as a cause of liver injury as C (probable rare cause of clinically apparent liver injury), with the cases having all the characteristics of idiosyncratic liver injury rather than direct toxicity. Latency was between 2 to 8 weeks and resembled acute hepatitis with a hepatocellular pattern of serum enzyme elevations.

Two compounds isolated from M. citrifolia have been associated with hepatotoxicity: anthraquinones (dose-dependent) and coumarins (idiosyncratic); however, such causality needs to be further evaluated. Although several hepatotoxicity cases were reported, there is insufficient evidence to adequately assess the causality of noni as the causative agent.

A case of a 38-year-old woman who developed acute liver injury associated with noni juice consumption while on long-term (9 months) anticonvulsant therapy has been reported; clinical presentation and liver biopsy were consistent with severe, predominantly hepatocellular type of injury.

A pediatric case is notable: a case of acute hepatotoxicity after ingestion of an energy drink containing noni berries was reported in a previously healthy 14-year-old boy, who presented with fatigue and scleral icterus. Initial tests demonstrated an alanine aminotransferase (ALT) elevated to 3,000 U/L with direct bilirubin of 4.4 mg/dL and INR of 1.6. The patient had a peak ALT of 3,407 U/L and peak direct bilirubin of 12.3 mg/dL, which normalized two months after cessation of noni berry juice consumption; the patient recovered completely.

8.2 Potassium and Hyperkalemia

Noni contains relatively high levels of potassium (similar to levels in orange and tomato juice), and a case of hyperkalemia was reported in a patient with chronic renal insufficiency. Due to the potassium content of some noni juice products, there is a potential for interaction with drugs causing increased potassium levels. Individuals with renal impairment or those taking potassium-sparing diuretics or ACE inhibitors should be aware of this risk.

8.3 Drug Interactions

Warfarin/Anticoagulants: One case has been reported of resistance to the anticoagulant coumadin due to the vitamin K content of the particular noni product being used by the patient. There is a theoretical risk of reduced warfarin effects.

Phenytoin: A case of unsafe interaction between a commercial product of noni juice and phenytoin has been reported. Persistent subtherapeutic phenytoin levels (<10 mg/L) and poor seizure control were observed in an epileptic patient who co-administered noni fruit juice daily.

Phenobarbital (and anticonvulsants generally): In a reported drug-herb interaction case, both the noni juice and the anticonvulsant (phenobarbital) were stopped and corticosteroids were initiated; the patient had fully recovered five months later.

Gastrointestinal motility drugs (theoretical): A single-dose, randomized, open-label, 2-period crossover study in 20 healthy volunteers showed that the aqueous fruit extract influenced the motor activity of the gastrointestinal tract. The fruit extract enhanced the rate and extent of ranitidine absorption, partly due to the ability of its active component scopoletin to stimulate the 5-HT4 receptor.

Antihypertensives (theoretical): There is a theoretical risk of hypotension in those treated with antihypertensives.

8.4 EU Regulatory Status

Noni juice was approved as a novel food by the European Commission in 2003. An EFSA Panel concluded that, on the basis of data provided, the use of dried noni leaves for preparation of infusions was safe (EFSA 2008).

8.5 Genotoxicity Considerations

Morinda citrifolia (noni) is known to contain genotoxic anthraquinones in the roots. Because of the widespread use of noni juice, the possible genotoxic risk has been examined through a battery of short-term tests. Commercial noni juice is primarily derived from the fruit pulp and juice, which contains far lower concentrations of anthraquinones than the roots; formal testing of commercial juice fractions found no genotoxic signal at tested concentrations. Nevertheless, this remains an area of monitoring interest given the structural class of anthraquinone compounds.

---

References

• Morinda citrifolia L.: A Comprehensive Review on Phytochemistry, Pharmacological Effects, and Antioxidant Potential — PMC / Antioxidants (2025)
• Antibacterial Constituents of Hainan Morinda citrifolia (Noni) Leaves — PubMed
• Chemical constituents of the fruits of Morinda citrifolia (Noni) and their antioxidant activity — PubMed
• Review of the ethnobotany, chemistry, biological activity and safety of the botanical dietary supplement Morinda citrifolia (noni) — Journal of Pharmacy and Pharmacology (Wiley, 2007)
• Morinda officinalis How. — A comprehensive review of traditional uses, phytochemistry and pharmacology — ScienceDirect / Journal of Ethnopharmacology (2017)
• A high-quality genome assembly of Morinda officinalis, a famous native southern herb in the Lingnan region of southern China — Horticulture Research (Nature, 2021)
• Noni — LiverTox®, NCBI Bookshelf, NIH
• Efficacy and Safety of Morinda citrifolia L. (Noni) as a Potential Anticancer Agent — PMC / Integrative Cancer Therapies (2022)
• Morinda citrifolia (Noni) as an Anti-Inflammatory Treatment in Women with Primary Dysmenorrhoea: A Randomised Double-Blind Placebo-Controlled Trial — PMC
• Antioxidant activity of noni juice in heavy smokers — PMC
• Noni Juice Improves Serum Lipid Profiles and Other Risk Markers in Cigarette Smokers — PMC / Scientific World Journal (2012)
• Noni juice reduces lipid peroxidation–derived DNA adducts in heavy smokers — PMC / Food Science & Nutrition
• Morinda citrifolia and Its Active Principle Scopoletin Mitigate Protein Aggregation and Neuronal Apoptosis through Augmenting the DJ-1/Nrf2/ARE Signaling Pathway — PMC
• Damnacanthal is a potent inducer of apoptosis with anticancer activity by stimulating p53 and p21 genes in MCF-7 breast cancer cells — PMC
• Xeronine structure and function: computational comparative mastery of its mystery — PMC
• Identification of Anti-Inflammatory Compounds from Hawaiian Noni (Morinda citrifolia L.) Fruit Juice — PMC
• Morinda citrifolia L. fruit extracts modulates H2O2-induced oxidative stress in human liposarcoma SW872 cells — PMC
• Morinda officinalis oligosaccharides increase serotonin in the brain and ameliorate depression via promoting 5-hydroxytryptophan production in the gut microbiota — PMC / Acta Pharmaceutica Sinica B (2022)
• Optimization of Extraction Process, Preliminary Characterization and Safety Study of Crude Polysaccharides from Morindae Officinalis Radix — PMC
• Research progress on the oligosaccharide components and pharmacological activities of Morinda officinalis — PMC
• A high-quality genome assembly of Morinda officinalis — PMC / Horticulture Research (2021)
• Simultaneous Analysis of Iridoid Glycosides and Anthraquinones in Morinda officinalis Using UPLC-QqQ-MS/MS and UPLC-Q/TOF-MSE — PMC
• Structural Characterization and Discrimination of Morinda officinalis and Processing Morinda officinalis Based on Metabolite Profiling Analysis — PMC
• Hepatotoxicity of NONI juice: Report of two cases — PMC / World Journal of Gastroenterology
• Drug-Induced Liver Injury Associated with Noni (Morinda citrifolia) Juice and Phenobarbital — PMC
• Acute Hepatotoxicity After Ingestion of Morinda citrifolia (Noni Berry) Juice in a 14-year-old Boy — PMC
• Food-drug interactions precipitated by fruit juices other than grapefruit juice: An update review — PMC
• Noni (Morinda citrifolia) — CAM-Cancer.org
• From Polynesian healers to health food stores: changing perspectives of Morinda citrifolia (Rubiaceae) — PubMed / Integrative Cancer Therapies (2003)
• Noni enhances the anticancer activity of cyclophosphamide and suppresses myelotoxicity and hepatotoxicity in tumor-bearing mice — PMC
• Morinda citrifolia — Encyclopædia Britannica